Pacira (PCRX) director receives RSU and stock option grants

Rhea-AI Filing Summary

Pacira BioSciences director Christopher Christie received new equity compensation awards. He was granted 6,405 restricted stock units that vest on June 10, 2027, as long as he remains in continuous service with the company through that date. Each unit represents one share of common stock. He also received a stock option for 10,891 shares of common stock at an exercise price of $23.42 per share, which vests and becomes exercisable on June 10, 2027 and expires on June 10, 2036. Following these awards, Christie directly holds 23,059 shares of Pacira common stock. These are compensation-related grants, not open-market purchases or sales.

Insights

Equity compensation analyst

Director received routine equity grants, adding stock exposure without open-market buying or selling.

Director Christopher Christie was awarded 6,405 restricted stock units and a stock option for 10,891 shares at $23.42 per share. Both awards vest on June 10, 2027, subject to continued service, and the option expires on June 10, 2036.

These A-code transactions are standard compensation rather than discretionary trades, so they carry limited signaling value about Christie's view of the stock. After the grants, he directly owns 23,059 common shares, giving him increased equity alignment with shareholders without any shares being sold.

Because 0% of these awards involved open-market activity and there are no remaining derivatives listed beyond this option, the filing mainly documents ongoing incentive structures. Future company filings may show how much of these awards ultimately vest and are retained over time.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider CHRISTIE CHRISTOPHER

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,891	$0.00	--
Grant/Award	Common Stock	6,405	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 10,891 shares (Direct, null); Common Stock — 23,059 shares (Direct, null)

Footnotes (1)

1. Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Key Figures

Restricted stock units granted: 6,405 units Stock options granted: 10,891 options Option exercise price: $23.42 per share +3 more

6 metrics

Restricted stock units granted 6,405 units Vest on June 10, 2027, one unit per share

Stock options granted 10,891 options Right to buy common stock, granted June 10, 2026

Option exercise price $23.42 per share Conversion or exercise price for new option grant

Option vesting date June 10, 2027 Options vest if continuous service is maintained

Option expiration date June 10, 2036 Final date to exercise vested options

Shares held after transaction 23,059 shares Direct common stock holdings following grants

Key Terms

restricted stock units, stock option, continuous service, exercise price, +1 more

5 terms

restricted stock units financial

"Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock option financial

"The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

continuous service financial

"provided that the reporting person remains in continuous service with the issuer through the vesting date"

exercise price financial

"conversion_or_exercise_price": "23.4200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

exercisable financial

"The stock option vests and becomes exercisable on June 10, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHRISTIE CHRISTOPHER

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		A		6,405(1)	A	$0	23,059	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.42	06/10/2026		A		10,891		06/10/2027(2)	06/10/2036	Common Stock	10,891	$0	10,891	D

Explanation of Responses:

1. Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

2. The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Pacira BioSciences (PCRX) director Christopher Christie receive?

Christopher Christie received 6,405 restricted stock units and a stock option for 10,891 shares of Pacira common stock. Both awards were granted at no cash cost to him as compensation, increasing his potential future ownership stake in the company if they vest.

When do Christopher Christie’s new Pacira (PCRX) restricted stock units vest?

Christie’s 6,405 restricted stock units vest on June 10, 2027, provided he remains in continuous service with Pacira through that date. Each vested unit will convert into one share of Pacira common stock upon settlement, directly linking his compensation to the company’s equity performance.

What are the key terms of Christopher Christie’s new Pacira (PCRX) stock option grant?

Christie received a stock option covering 10,891 shares at an exercise price of $23.42 per share. The option vests and becomes exercisable on June 10, 2027, assuming continued service, and remains exercisable until its expiration on June 10, 2036, if vested.

How many Pacira (PCRX) shares does Christopher Christie hold after these grants?

Following the equity awards, Christopher Christie directly holds 23,059 shares of Pacira common stock. This figure reflects his position after the 6,405 restricted stock units were granted, although those units still must vest before becoming freely owned shares he can sell or retain.

Do Christopher Christie’s Pacira (PCRX) Form 4 transactions involve stock sales or open-market purchases?

The reported transactions are compensation-related grants, not open-market purchases or sales. Both the restricted stock units and stock option were awarded at a price of $0.00 per share, reflecting equity incentives rather than discretionary trading activity in Pacira stock on the open market.